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Abstract Binding assays using 2-[125I]iodomelatonin revealed 
high-affinity, guanosine 5'-0-(3-thiotriphosphate) sensitive, mel-
atonin binding sites ( ß m a x 1.1 fmol/mg protein) in the human 
embryonic kidney cell line HEK293. Competition studies using 
the selective melatonin receptor antagonist luzindole and RT-
PCR techniques identified these sites as human Meli a melatonin 
receptors. Challenge of HEK293 cells with 1 pM melatonin had 
no effect on forskolin stimulated cyclic AMP levels, whereas in 
HEK293 cells engineered to stably over-express the human 
Melia melatonin receptor ( ß m a x > 400 fmol/mg protein) mela-
tonin dose-dependently inhibited stimulated cyclic AMP levels 
(IC5 0 7.7 pM). These data may indicate that certain tissues, 
expressing low levels of G protein-coupled melatonin receptors, 
do not display melatonin mediated inhibition of cAMP. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Melatonin has been shown to play a role in the control and 
regulation of several mammalian biological systems. The best 
characterised of these are the regulation of circadian rhythms 
[1], and the control of aspects of reproductive state in season-
ally breeding mammals [2]. Melatonin acts on these systems 
by stimulating cell surface melatonin receptors found in the 
hypothalamic suprachiasmatic nucleus, and the pars tuberalis 
of the pituitary respectively [3,4]. Melatonm receptors were 
localised on these tissues by ligand binding experiments and 
in vitro autoradiography using the high-affinity radioligand 
125I-Mel [5]. Many other tissues, both central and peripheral, 
have also had melatonin receptors identified using 125I-Mel 
(review [6]), but the possible effects of melatonin on the cel-
lular regulation of these tissues remains poorly characterised. 
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Abbreviations: G protein, heterotrimeric guanine nucleotide-binding 
protein; RT-PCR, reverse-transcription polymerase chain reaction; 
PBS, phosphate buffered saline; EGTA, ethylene glycol-bis(ß-ami-
noethyl ether) JV,JV,JV',JV'-tetraacetic acid; PEG 8000, polyethylene 
glycol (average molecular weight 8000); IBMX, 3-isobutyl-l-methyl-
xanthine; TCA, trichloroacetic acid; M-MLV, Moloney leukaemia 
virus; DTT, dithiothreitol; dNTP, deoxyribose nucleotide 5'-triphos-
phate 
One tissue which displays guanosine 5'-0-(3-thiotriphos-
phate) (GTPyS) sensitive 125I-Mel binding, indicative of G-
protein-coupled melatonin receptors, is the mammalian kid-
ney. Recently melatonin receptors have been identified in hu-
man adult kidney [7], human fetal kidney [8] and adult guinea 
pig kidney [9,10]. Several reports identify circadian and mel-
atonin mediated changes on mammalian kidney function 
[11,12] suggesting the possible direct action of melatonin on 
mammalian kidney via the identified melatonm receptors. Ad-
ditional evidence of direct melatonm action on vertebrate kid-
ney is provided by the identification of a melatonin mediated 
inhibition of forskolin stimulated cyclic A M P (cAMP) levels 
in expiants of chicken kidney [13]. 
Investigations on possible melatonin mediated effects on 
human kidney are hampered by the lack of available tissue, 
however human embryonic kidney tissue has been trans-
formed using adenovirus type 5 D N A to generate the cell 
line HEK293 [14] which may provide a suitable model for 
investigations to be performed. Here we report the identifica-
tion of GTPyS sensitive human Meli a melatonin receptors in 
HEK293 cells and investigate the melatonm mediated effect 
on forskolin stimulated c A M P levels. To our knowledge 
HEK293 is the first mammalian (human) cell line shown to 
express melatonin receptors. 
2. Materials and methods 
2.1. Materials 
HEK293 cells were provided by the European Collection of Animal 
Cell Cultures. Tissue culture media, supplements and sera were ob-
tained from Life Technologies Inc. 125I-Mel (2200 Ci/mmol) was pur-
chased from NEN DuPont. Melatonin and other drugs were pur-
chased from Sigma, except 2-iodomelatonin was obtained from 
Research Biochemicals Inc. All other reagents used in this study 
were purchased from Sigma. 
2.2. Culture of HEK293 cells 
HEK293 cells were cultured as monolayers in Eagle's minimum 
essential medium (EMEM) supplemented with 10% (v/v) fetal calf 
serum and 1% (v/v) antibiotic/antimycotic solution, in 5% (v/v) C0 2 
at 37°C. When required for ligand binding experiments confluent 
plates were washed twice with PBS (pH 7.4) and harvested by gentle 
scraping. Cells were pelleted by centrifugation (13 000Xg, 1 min) and 
stored in aliquots at —80°C. 
2.3. Stable transfection of HEK293 cells 
A cloning methodology involving the screening a human genomic 
DNA library (Clontech) and PCR of human genomic DNA was used 
to isolate sequences encoding human Melia [15] and human Meln> [16] 
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melatonin receptors. The full coding sequence of each receptor was 
subcloned into pcDNA 3 (Invitrogen) and confirmed by DNA se-
quencing. Recombinant plasmids were introduced into HEK293 cells 
using the lipid transfection reagent DOTAP (Sigma). Cells were cul-
tured in supplemented EMEM containing G-418 (0.5 mg/ml) until 
resistant clones were apparent. Individual clones were tested for 
125I-Mel binding and positive clones, expressing > 100 fmol of recep-
tor/mg protein, were maintained for subsequent experiments. 
2.4. l2bI-Mel equilibrium ligand binding 
Equilibrium 12BI-Mel binding experiments were performed in glass 
test tubes in a final reaction volume of 200 u.1 of 'ligand binding 
buffer' (10 mM Tris-HCl pH 7.5, 1 mM EGTA), for 2 h at 37°C. 
For experiments using untransfected HEK293 cells 200-500 u.g of cell 
protein per tube was used, while binding experiments using human 
Melia or human Melib stably transfected HEK293 cells typically had 
2-4 |xg of cell protein per tube. Protein determinations were per-
formed in duplicate by the method of Bradford [17]. Binding reactions 
were terminated by rapid cooling on ice, followed by addition of 0.8 
ml 0.1% (w/v) sheep y-globulin and 1.0 ml of 24% (w/v) PEG 8000 
(both dissolved in ice-cold ligand binding buffer). Samples were vortex 
mixed and the precipitated 125I-Mel bound protein fraction was re-
covered by centrifugation (1800 Xg, 30 min at 4°C). The supernatant 
was poured off and the protein pellet resuspended by vigorous vortex-
ing in 2 ml of 12% (w/v) PEG 8000, 0.05% (w/v) sheep y-globulin and 
recovered by centrifugation as above. The supernatant was poured off 
and the pellet allowed to air dry before being counted on a Packard 
Cobra y-counter. All determinations were performed in duplicate or 
triplicate and all experiments repeated at least 3 times. Analysis of 
ligand binding was performed using the GRAFIT software package 
(Sigma). 
2.5. RT-PCR ofHEK293 cell mRNA 
Messenger RNA was isolated from HEK293 cells using a Message 
Maker mRNA isolation kit ( R & D Systems) according to the man-
ufacturer's instructions. First strand cDNA was synthesised from 1 |ig 
of mRNA in 1 X transcription buffer using 0.5 u.g of random primers 
and 200 U of M-MLV reverse transcriptase in the presence of 0.8 mM 
DTT, 25 U of RNA guard and 1 mM dNTPs. PCR was performed on 
2 |xl aliquots of the 20 ul first strand cDNA reaction using human 
Melia or human Melib specific oligo primers (see Fig. 2a). The primer 
pairs used were designed to give amplification between exon 1 and 
exon 2 of the melatonin receptor gene thus eliminating amplification 
of genomic DNA. Hot start PCR was performed using 100 pmol of 
each primer, 2.5 U of AmpliTaq in the presence of 200 uM dNTPs 
and 1.5 mM MgCb. The PCR reaction cycles consisted of 94°C for 
1 min, 58°C for 1.5 min and 72°C for 1.5 min for 35 cycles. Control 
reactions were performed with 1 |j,g of HEK293 mRNAs as above 
after RNase or DNase treatment. To ensure that solutions used for 
reverse transcription were free of contaminating sequences control 
reactions were processed without the addition of mRNA. 
The PCR products were electrophoresed through 1% agarose gels 
and Southern blotted onto GeneScreen Nylon filters (NEN Dupont) 
using a pressure blotter (Stratagene). A human Melia oligonucleotide, 
designed to hybridise to a site internal to the human Melia specific 
PCR primers, was end labelled with 32P dCTP (Amersham) by stand-
ard procedures utilising terminal deoxynucleotidyl transferase. The 
filters were stripped and reprobed with a human Melib specific oligo-
nucleotide probe internal to the human Melib specific PCR primers. 
Hybridisation was performed at 65°C in QuikHyb (Stratagene) ac-
cording to the manufacturers instructions. The filters were washed 
to a final stringency of 1X SSC at 60°C. PCR products giving a 
positive hybridisation signal were subcloned using a pGEM-T vector 
system (Promega) and DNA was prepared for sequencing to confirm 
the identity of the PCR products. 
2.6. DNA sequencing 
DNA was prepared for sequencing using a Wizard 373A DNA 
purification kit (Promega) according to the manufacturer's instruc-
tions. DNA sequencing was performed by using the Prism Dye-Deoxy 
terminator sequencing kit (ABI) and samples run and analysed using 
an Applied Biosystems model 373 DNA sequencer. 
2.7. cAMP determinations of HEK293 
Untransfected or stably transfected HEK293 cells were seeded into 
poly-D-lysine coated 24 well tissue culture plates at 2X106 cells per 
well. Following incubation for 24 h the growth medium was aspirated 
and the cells washed once with 0.5 ml of supplement free EMEM. The 
wash medium was removed and 0.5 ml EMEM (containing 10~3 M 
IBMX) and appropriate concentrations of drugs added for 30 min at 
37°C. Routinely cAMP levels were stimulated with 10~5 M forskolin 
and melatonin effects were analysed over the range of 10~13-10~6 M 
melatonin. Reactions were stopped by removal of the assay medium 
and addition of 0.4 ml 5% (w/v) TCA solution. cAMP determinations 
were performed on the TCA extract by radioimmunoassay as previ-
ously described [18]. Each experimental treatment was performed on 
3 individual wells, with each well assayed in duplicate. Experiments 
were repeated at least 3 times. 
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Fig. 1. 125I-Mel saturation binding. Saturation curves in the absence 
(open circles) or presence (filled circles) of 10~4 M GTPyS. a: 
HEK293; b: HEK293 stably transfected with human Melia melato-
nin receptor; c: HEK293 stably transfected with human Melib mel-
atonin receptor. Data shown are from a single experiment using 
mean values of triplicate determinations, and are representative of 3 
or 4 similar experiments. All data are fitted with single-site satura-
tion curves calculated using the GRAFIT software. Calculated K^ 
and 5 m a x values ± S.E.M. are listed in Section 3. 
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Fig. 2. a: Schematic diagram of melatonin receptor cDNA showing location of primer sites. The primer pair shown above the diagram of the 
melatonin receptor cDNA are specific for the human Melia receptor and consist of P1MEL1A (5'-CTGGCCTGCGTCCTCATCTTCAC-
CATCGTG-3'), positions 88-117 and P2MEL1A (5'-CCATGCTGGCGGGGTCAGAGGC-3'), positions 784-805. The primer pair shown be-
low the diagram are specific for the human Mellb receptor and consist of P1MEL1B (5'-CGCTGTCCGCGGTGCTCATCGTCACCACC-3'), 
positions 125-153 and P2MEL1B (5'-CCAGGGCCCAGCCGTCATAGAAGATG-3'), positions 300-325. The size of the PCR product ob-
tained with each primer pair is indicated. The splice site between exon 1 and exon 2 of melatonin receptor genes is indicated by the vertical 
line between transmembrane domains I and II in the diagram, b: RT-PCR for melatonin receptor gene expression in HEK293 cells. A Melia 
specific 32P-radiolabeled oligonucleotide probe (5'-TGCGTTCCTGAGCTTCTTGTTCCGATACAC-3', positions 154-183) and a Mellb specific 32P-radiolabeled oligonucleotide probe (5'-TGCGTTCCGGAGCTTGCGGTTCCTGAGCAC-3', positions 193-222) internal to the PCR pri-
mers showed hybridisation to products of the appropriate size using the PCR primers indicated. These RT-PCR products were subcloned and 
confirmed by DNA sequencing. 
3. Results 
3.1. 125I-Mel saturation binding 
Specific 125I-Mel binding was observed in HEK 293 cells 
(KA 23.5 ±2.8 pM, ßm a x 1.11 ±0.02 fmol/mg protein; 
mean ± S.E.M., n = 4) (Fig. la). The binding had a similar 
Kd value to stably transfected HEK293 cells over-expressing 
either the human Melia melatonin receptor (Àj 22.8 ± 3.3 pM, 
Bms,x 567.7 ±96.4 fmol/mg protein; mean±S.E.M., w = 3) 
(Fig. lb), or the human Melib melatonin receptor (K^ 
80.3 ±18.7 pM, 5 m a x 432.0 ±84.6 fmol/mg protein; 
mean ± S.E.M., « = 3) (Fig. lc). The 125I-Mel binding in 
HEK293 cells was sensitive to 10~4 M GTPyS (Kd 38.5 ±3.4 
pM, £max 0.72±0.06 fmol/mg protein; mean±S.E.M., n = A) 
(Fig. la), as was the binding observed in the HEK293 clones 
stably expressing the human Mel la melatonin receptor (Kd 
161.1 ±24.4 pM, BmSK 536.2 ±74.2 fmol/mg protein; 
mean ± S.E.M., n = 3) (Fig. lb), or the human Melib receptor 
(Kd 298.6 ±25.6 pM, 5 m a x 369.3 ±52.1 fmol/mg protein; 
mean±S.E.M., n = 3) (Fig. lc). Therefore it would seem 
that HEK293 cells express high affinity G protein-coupled 
melatonin receptors. 
3.2. RT-PCR of human Mel\& and Melvo melatonin receptor 
transcripts 
To confirm if HEK293 cells possess the genes encoding for 
either of the two cloned human melatonin receptors, RT-PCR 
was performed on HEK293 mRNA with either human Melia 
or human Melib specific primers (Fig. 2a). Amplified products 
were resolved by agarose gel and Southern blotted, using spe-
cific human Melia and human Melib oligonucleotide probes, 
internal to the amplification primers. Both human Melia and 
human Melib specific products were identified on a Southern 
blot (Fig. 2b) and confirmed by subcloning and DNA se-
quencing. DNase treatment of HEK293 mRNAs prior to 
RT-PCR did not eliminate amplification of PCR products 
hybridising to Melia and Melib specific oligo probes. No hy-
bridising PCR products were observed in reagent controls and 
RT-PCR products were eliminated in samples treated with 
RNase prior to RT-PCR. These data suggest that HEK293 
contains both human Melia and human Melib mRNA tran-
scripts. This experiment however was not quantitative and 
therefore no indication of the relative abundance of each re-
ceptor transcript could be inferred. 
3.3. Competitive displacement of125I-Mel binding 
To characterise the HEK293 melatonin receptor competi-
tive displacement of 125I-Mel binding (100 pM 125I-Mel con-
centration) was performed with 5 drugs: 2-iodomelatonin, 
melatonin, 6-hydroxymelatonin, JV-acetylserotonin and luzin-
dole. Parallel experiments were also performed on the stably 
transfected HEK293 cells over-expressing either the human 
Melia or human Melib melatonin receptor to allow direct 
comparison of results. Four of these drugs: 2-iodomelatonin, 
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Fig. 3. Competitive displacement of 125I-Mel binding in HEK293. Competitive displacement of 125I-Mel binding using 5 drugs was performed 
on, HEK293 (filled circles), HEK293 stably transfected with human Melia melatonin receptor (open squares) and HEK293 stably transfected 
with human Melib melatonin receptor (open circles). Each set of data was normalised to percentage relative binding and plotted on individual 
graphs. Data shown are means of duplicate determinations from a single experiment ±S.E.M., and are representative of 3 or 4 similar experi-
ments. Each set of data is fitted with a 4-parameter logistic competition curve calculated by the GRAFIT software. K[ values (and slope fac-
tors) for HEK293 (mean ± S.E.M., n = 3); 2-iodomelatonin, 4.28 ± 0.23 X 10~n M (1.00 ±0.02); melatonm, 2.81 ±0.23 X 10"10 M (0.89 ±0.03); 6-
hydroxymelatonin, 1.89±0.03X 10 - 9 M (1.10±0.07); W-acetylserotonin, 4.06 ± 0.54 X 10 - 7 M (1.00±0.02); luzindole, 5.29 ± 0.09 X 10 - 7 M 
(1.02 ±0.01). 
melatonin, 6-hydroxymelatonin and ./V-acetylserotonin gave 
essentially similar results for HEK293 and both stably trans-
fected clones (Fig. 3). These values were consistent with those 
originally identified for human Melia and human Melib mel-
atonin receptors [15,16] and support the RT-PCR data that 
the identified melatonin receptors in HEK293 are human 
Melia and/or human Melib. The fifth drug, luzindole [19], 
was selective for human Melib (IC50 1.84 ± 0.03 X 10"7 M, 
mean±S.E.M., n-3) over human Melia (IC50 
3.35 ± 0.13 XlO - 6 M, mean±S.E.M., « = 4) by a factor of 
18.2, consistent with previous reports [20]. HEK293 cells 
gave an IC50 value for luzindole of 2.78 ±0.05 X10 - 6 M, 
(mean ± S.E.M., « = 3) very similar to that obtained for the 
stably transfected human Melia clone (Fig. 3). These data 
identify the expression of only human Melia melatonin recep-
tors in HEK293. 
3.4. Effect of melatonin on cAMP levels in HEK293 
HEK293 cells did not display a melatonin mediated effect 
on 10~5 M forskolin stimulated cAMP levels (Fig. 4a), where-
as stably transfected HEK293 cells over-expressing human 
Melia or human Melib melatonin receptors displayed almost 
complete inhibition of cAMP at physiological melatonin con-
centrations, with IC50 values of 7.7 pM and 117 pM respec-
tively (Fig. 4b,c). 
4. Discussion 
125I-Mel saturation binding identifies HEK293 as the first 
mammalian (human) cell line in which high-affinity G-protein-
coupled melatonin receptors have been detected. This is con-
sistent with the previous identification of melatonin receptors 
in fetal human kidney [8]. RT-PCR suggests that HEK293 
cells have transcripts encoding for both human Melia and 
human Melib subtypes, but competitive displacement of 125I-
Mel binding by luzindole revealed that only the Melia recep-
tor was expressed at detectable levels. This is again consistent 
with fetal human kidney in which Melia and Melib receptor 
transcripts were identified by RT-PCR but only Melia was 
identified by in situ hybridisation [8]. Therefore Melia tran-
scripts appear to be present at levels above those of Melib 
transcripts in human fetal kidney and suggest that Melia re-
ceptors are preferentially expressed. Such preferential expres-
sion would explain our finding of only Melia receptors in 
HEK293, although Melib receptors may be expressed at 
very low undetectable levels. The significance of this differ-
ential expression of melatonin receptor subtypes remains un-
clear. Note : During the preparation of this manuscript Song 
et al. [10] discussed initial findings of 125I-Mel binding in 
HEK293 and reported the identification of a 37 kDa protein 
immunoreactive to peptide derived anti-Melia antibodies. This 
would appear consistent with our findings. 
Functionally HEK293 cells did not display melatonin medi-
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Fig. 4. Effect of melatonm of forskolin stimulated cAMP levels in 
HEK293. a: HEK293 (mean of 3 experiments±S.E.M.); b: 
HEK293 stably transfected with human Melia melatonin receptor 
(mean of single experiment with duplicate determinations of tripli-
cate points ± S.E.M., repeated 3 times); c: HEK293 stably trans-
fected with human Melib melatonin receptor (mean of single experi-
ment with duplicate determinations of triplicate points ± S.E.M., 
repeated 3 times). Basal cAMP levels (filled circles), incubation with 
10 -6 M melatonin alone (filled squares), incubation with 10~5 M 
forskolin ± melatonin (0, 10_ 1 3-10 - 6 M) (open circles). IC50 values 
were determined by the GRAFIT software and were 7.67 X 10 -12 M 
for Melia receptor and 1.17X10-10 M for the Melib receptor. 
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ated effects on forskolin stimulated cAMP levels, whereas 
HEK293 cells over-expressing either human Mel la or human 
Melib melatonin receptors almost completely inhibited stimu-
lated cAMP levels at physiological melatonin levels (see Fig. 
4). The lack of effect in untransfected HEK293 is consistent 
with the previous report of Yung et al. [21] in which melato-
nin displayed no effect (P>0.9) on hormone stimulated 
cAMP levels in HEK293. These authors did not know that 
HEK293 had a native melatonin receptor and performed this 
experiment as a control in their studies. As the human Melia 
stably transfected HEK293 cells displayed an inhibition of 
cAMP there would appear to be a receptor concentration 
dependent phenomenon, i.e. HEK293 are unresponsive to 
melatonin if Melia melatonin receptors are expressed at 1.1 
fmol/mg protein but responsive at 400 fmol/mg protein. The 
large difference in these ßm a x values is not ideal, however it 
does illustrate that there may be a level below which melato-
nin receptors, despite being G-protein coupled, are not able to 
modulate cellular cAMP levels in HEK293. Interestingly there 
also appears to be a difference in the GTPyS effect on 
HEK293 compared to the stably transfected cells. HEK293 
displays an approximately 2-fold reduction in K& and a 35% 
reduction in fimax whereas the Melia stably transfected cells 
show a 6-7-fold reduction in fQ but no change in _Bmax (see 
Fig. 1). Therefore it is possible that the nature of the G-pro-
tein-coupling is different in untransfected HEK293 compared 
to the Mel la transfected cells. As many mammalian tissues, 
including the kidney, have similar reported levels of 125I-Mel 
binding to HEK293 (ca. 1 fmol/mg protein) this may indicate 
that melatonin does not have a significant effect on signalling 
through cAMP inhibition in these tissues. The identification 
of an ~ 40% inhibition of stimulated cAMP levels in expiants 
of chicken kidney (receptor 5 m a x ~1.5 fmol/mg protein) [13] 
appears to confound this proposal. However, localisation data 
on human fetal kidney [8] and guinea pig kidney [10] would 
appear to indicate that expression of melatonin receptors in 
the kidney is restricted to specific cell types, therefore the 5 m a x 
reported in chicken kidney may be an under-representation of 
melatonin receptor density of these cells. These data could 
also indicate that tissues may display different responses to 
melatonin in a tissue and/or species dependent manner. 
The identification of G protein-coupled Melia melatonin 
receptors in HEK293 provides an accessible system for the 
study of melatonin mediated effects on human derived tissue. 
This cell line may provide valuable insights into melatonin 
receptor action which will be difficult to study on native hu-
man tissue and could reveal subtleties in melatonin mediated 
signal transduction pathways which may not be apparent by 
using transfected cell systems. 
Acknowledgements: We thank April Newman for performing the 
DNA sequencing. This work was supported by SOAEFD and a grant 
from Servier, France. 
References 
[1] V.M. Cassone, Trends Neurosci 13 (1990) 457^164. 
[2] G.A. Lincoln, J Endocrinol 142 (1994) 267-276. 
[3] P.J. Morgan, L.M. Williams, G. Davidson, W. Lawson, E. Ho-
well, J Neuroendocrinol 1 (1989) 1-4. 
[4] S.M. Reppert, D.R. Weaver, S.A. Rivkees, E.G. Stopa, Science 
242 (1988) 78-81. 
[5] O. Vakkuri, E. Lamsa, E. Rahkamaa, H. Ruotsalainen, J. Lep-
paluoto, Anal Biochem 142 (1984) 284-289. 
[6] P.J. Morgan, P. Barrett, H.E. Howell, R. Helliwell, Neurochem 
Int 24 (1994) 101-146. 
[7] Y. Song, P.C. Tam, A.M.S. Poon, G.M. Brown, S.F. Pang, J Clin 
Endocrinol Metab 80 (1995) 1560-1565. 
[8] J.E. Drew, L.M. Williams, L.T. Hannah, P. Barrett, D.R. Abra-
movich, P.J. Morgan, J Endocrinol (Suppl) 151 (1996) P76. 
[9] Y. Song, A.M.S. Poon, P.P.N. Lee, S.F. Pang, J Pineal Res 15 
(1993) 153-160. 
[10] Y. Song, C.W.Y. Chan, G.M. Brown, S.F. Pang, M. Silverman, 
FASEB J 11 (1997) 93-100. 
[11] B.A. Richardson, E.H. Studier, J.N. Stallone, CM. Kennedy, 
J Pineal Res 13 (1992) 49-59. 
[12] T. Tsuda, M. Ide, M. Iigo, J Pineal Res 19 (1995) 166-172. 
[13] Y. Song, C.S. Pang, G.M. Brown, S.F. Pang, Eur J Endocrinol 
135 (1996) 128-133. 
[14] F.L. Graham, J. Smiley, W.C. Russell, R. Nairn, J Gen Virol 36 
(1977) 59-72. 
[15] S.M. Reppert, D.R. Weaver, T. Ebisawa, Neuron 13 (1994) 
1177-1185. 
[16] S.M. Reppert, C. Godson, CD. Mahle, D.R. Weaver, S.A. Slau-
genhaupt, J.F. Gusella, Proc Natl Acad Sei USA 92 (1995) 8734-
8738. 
[17] M.M. Bradford, Anal Biochem 72 (1976) 248-254. 
[18] P.J. Morgan, G. Davidson, W. Lawson, P. Barrett, J Neuroen-
docrinol 2 (1990) 773-776. 
[19] M.L. Dubocovich, J Pharmacol Exp Ther 246 (1988) 902-910. 
[20] M.L. Dubocovich, S. Iacod, K. Mistry, M.I. Masana, Soc Neu-
rosci Abstr 22 (1996) 1400. 
[21] LY. Yung, S.-T. Tsim, Y.H. Wong, FEBS Lett 372 (1995) 99-
102. 
